A Phase 2 interventional study of Salicylic Acid/Lactic Acid Topical Solution and Candida Antigen Intralesional Injection in Warts and Human Papilloma Virus (HPV), sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 5 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Benha University · Phase 2, Interventional, and Treatment
Objective: To compare the efficacy, safety, and recurrence rates of topical salicylic acid/lactic acid (SA/LA) monotherapy (Group A), intralesional Candida antigen (CA) monotherapy (Group B), and their combination (Group C) for the treatment of warts.
171 studies on the registry are indexed under Warts; 35 are open to participants now.
This study's enrollment of 126 is above the median of 70 across 155 interventional studies indexed under Warts.
Browse Warts studies →Benha University is the lead sponsor of 362 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.
Drug: Salicylic Acid/Lactic Acid Topical Solution
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.
Biological: Candida Antigen Intralesional Injection
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.
Combination Product: Candida Antigen and Salicylic Acid/Lactic Acid
Patients receive topical application of Salicylic Acid 40% and Lactic Acid 16% once daily for up to 6 weeks.
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions.
Drug pages: Candida albicans · Salicylic Acid · Lactic Acid
Patients receive intralesional injection of Candida Antigen (0.1-0.3 mL) every 2 weeks for up to 6 sessions, with topical Salicylic Acid 40% and Lactic Acid 16% applied in between.
Complete Response (CR) Rate
Percentage of patients achieving complete disappearance of all warts.
Time frame: 3 months post-treatment
Distant Wart Clearance Rate
Percentage of patients achieving clearance of non-injected/distant warts.
Time frame: 3 months post-treatment
Recurrence Rate
Percentage of patients with recurrence of warts after achieving CR.
Time frame: 6 months post-treatment
Safety and Tolerability Profile
Incidence and severity of local (pain, edema, crustations) and systemic (flu-like symptoms) side effects.
Time frame: At each visit (every 2 weeks) and 3 months post-treatment
Plan to share: Yes — What IPD will be shared? De-identified individual participant data that underlie the results reported in the final study, including demographic characteristics and ocular surface/meibomian gland assessment parameters. Supporting Documents: The study protocol and statistical analysis plan will be made available. When will data be available? Data will be available beginning 6 months and ending 36 months following the official publication of the study results. With whom? Data will be shared with qualified researchers who provide a methodologically sound proposal that is approved by the study investigators. For what types of analyses? To achieve the specific aims outlined in the approved research proposal. By what mechanism will data be made available? Interested researchers should contact the corresponding author via email to submit a formal request and a data use agreement.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available beginning 6 months and ending 36 months following the official publication of the study results.
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Candida albicans · Salicylic Acid · Lactic Acid